10-Q: Absci Corporation Reports First Quarter 2024 Financial Results, Highlights Pipeline Progress

Absci Corporation reported a net loss of $22.0 million for the first quarter of 2024, with technology development revenue of $0.9 million and a focus on advancing its integrated drug creation platform and internal pipeline.

Summary

• Absci Corporation reported a net loss of $22.0 million for the first quarter of 2024, compared to a net loss of $23.4 million for the same period in 2023.
• Technology development revenue was $0.9 million for the quarter, a decrease from $1.3 million in the first quarter of 2023.
• The company's research and development expenses decreased slightly to $12.2 million, down from $12.7 million in the prior year's quarter.
• Selling, general, and administrative expenses also decreased to $8.7 million from $9.6 million year-over-year.
• As of March 31, 2024, Absci had $161.5 million in cash, cash equivalents, and short-term investments.
• The company has an accumulated deficit of $428.5 million as of March 31, 2024.
• Absci is focusing on expanding its Integrated Drug Creation platform and advancing its internal asset pipeline, including ABS-101 which is expected to enter Phase 1 clinical trials in early 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has made progress in reducing its net loss and securing funding, the decrease in revenue and ongoing losses temper the positive aspects. The company's future success is heavily reliant on external factors, adding to the uncertainty.

Positives

• The net loss decreased year-over-year, indicating improved financial performance.
• The company successfully raised $80.8 million through a public offering of common stock.
• Absci is actively developing its internal pipeline, with ABS-101 progressing towards clinical trials.
• The company maintains a strong cash position with $161.5 million in cash, cash equivalents, and short-term investments.
• Absci has 16 active programs with partners, demonstrating continued engagement and market interest in its platform.

Negatives

• Technology development revenue decreased by 29% compared to the same quarter last year.
• The company continues to operate at a loss, with a net loss of $22.0 million for the quarter.
• Absci has an accumulated deficit of $428.5 million, highlighting the ongoing need for funding.
• The company's revenue is heavily reliant on a small number of partners, creating concentration risk.

Risks

• The company's future success is dependent on its ability to establish new partnerships and expand existing ones.
• There is no guarantee that partners will license the drug candidates created by Absci or that these candidates will be successfully developed and commercialized.
• The company's revenue is subject to fluctuations based on the timing of milestone achievements and partner decisions.
• Absci's ability to generate revenue is dependent on the successful development and commercialization of drug candidates by its partners, which is outside of its direct control.
• The company may need to raise additional capital in the future, which may not be available on favorable terms or at all.
• The company is subject to risks associated with drug development, including clinical trial failures and regulatory hurdles.

Future Outlook

Absci expects to continue to incur significant expenses as it implements its business development strategy, develops its internal pipeline, and invests in research and development. The company anticipates revenue growth from new partnerships and licensing agreements, but this is subject to the timing of milestones and partner decisions. Absci expects to initiate Phase 1 clinical studies for ABS-101 in early 2025.

Management Comments

• The company is focused on expanding its Integrated Drug Creation platform and advancing its internal asset pipeline.
• Absci aims to balance its portfolio between partnered programs and internal asset development to diversify risk and potential return on investment.
• Management believes that the company's unique approach has the potential to significantly shorten preclinical development timelines.
• The company is actively working to drive commercial adoption of its Integrated Drug Creation platform capabilities.

Industry Context

Absci operates in the competitive and rapidly evolving biopharmaceutical industry, focusing on antibody-based therapeutics. The company's Integrated Drug Creation platform, which combines AI with wet lab technologies, aims to improve upon traditional drug discovery methods. The company is competing with other companies developing biologics and AI-driven drug discovery platforms. The company is also aware of clinical stage assets targeting TL1A that are being developed by Merck, Roche and Sanofi.

Comparison to Industry Standards

• Absci's approach aims to shorten preclinical development timelines from the industry benchmark of 5-7 years to 18-24 months, which is a significant improvement if achieved.
• The company's focus on using AI to optimize multiple drug characteristics simultaneously is a differentiating factor compared to traditional methods.
• Absci's internal pipeline program ABS-101 is being compared to clinical stage assets targeting TL1A being developed by Merck, Roche and Sanofi, with Absci claiming potentially superior potency and developability properties.
• The company's ability to generate billions of antibody designs and screen millions of sequences in weeks is a significant advantage in terms of speed and scale compared to traditional methods.

Corporate Governance

Stakeholder Impact

• Shareholders may be impacted by the company's ongoing losses and the need for potential future capital raises.
• Employees are impacted by the company's continued investment in research and development and the potential for growth.
• Partners are impacted by the company's ability to deliver on its drug creation platform and the potential for future licensing agreements.
• Customers (potential patients) are impacted by the company's ability to develop new and improved therapeutics.

Next Steps

• Absci will continue to implement its business development strategy to drive adoption of its Integrated Drug Creation platform.
• The company will continue to develop its internal proprietary asset pipeline of lead drug candidates.
• Absci will continue to engage in research and development efforts to scale its drug creation activities.
• The company expects to initiate Phase 1 clinical studies for ABS-101 in early 2025.

Key Dates

Keywords

AI drug creation, biologics, antibody therapeutics, integrated drug creation platform, generative AI, drug discovery, preclinical development, clinical trials, milestone payments, royalties, internal pipeline, ABS-101, stock offering